

Reach for Zen.

Reach for

Zenrelia™ (ilunocitinib tablets)

Available in
30 count blister packs
and **90 count bottles**



Dog weight range (lbs)	Number of tablets to be administered daily			
	4.8 mg	6.4 mg	8.5 mg	15 mg
6.6–8.8	1			
8.9–11.8		1		
11.9–14.3			1	
14.4–17.7	1			
17.8–23.6		1		
23.7–31.1			1	
31.2–35.4	2	1		
35.5–43.1			2	1
43.2–55.0				1
55.1–62.5			2	2
62.6–83.3				2
83.4–110.0				3
110.1–137.5				3
137.6–166.0				3
≥166.1	Administer the appropriate combination of tablet strengths			

INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Read the entire package insert, including the Boxed Warning, before using this drug. For full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.

WARNING: INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of an inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to infections, including adenoviral hepatitis and pancreatitis. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

1. Forster S, Boegel A, Despa S, et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. *Veterinary Dermatology*. 2025; 1–10.

Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates. PM-US-24-0745(6)

Zenrelia is supplied in **4 strengths** and is dosed once daily at 0.27–0.36 mg/lb (0.6–0.8 mg/kg)



Once-daily dosing



Works Fast¹



No loading or tapering: can stop/start for short or long-term use



Hypoallergenic, unflavored oral tablet



Given with or without food, from the comfort of home

Visit
Zenreliaforvets.com

Elanco